{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344559","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2026-08-11T20:03:25+00:00","discovered_at":"2026-08-11T20:04:00.504907+00:00","generated_at":"2026-08-11T20:04:11.130967+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"enGene hosts Aug 11 virtual KOL event on NMIBC market research insights","bullets":["Virtual KOL event held August 11, 2026 to discuss emerging non-muscle invasive bladder cancer (NMIBC) market research.","Presentation filed as Exhibit 99.1; company positioned as non-viral genetic medicine developer.","No clinical data, financial results, or guidance disclosed in the filing; exhibit contains only title and disclaimers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344559","json":"https://secwatch.observer/filing/0001193125-26-344559.json","markdown":"https://secwatch.observer/filing/0001193125-26-344559.md","text":"https://secwatch.observer/filing/0001193125-26-344559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/0001193125-26-344559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/engn-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:04:11.130967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}